# PJA2 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - PJA2 is a RING-H2 E3 ubiquitin ligase crucial for proteostasis, regulating cell cycle progression, neuronal signaling, and immune responses by targeting substrates like AURKA and AKAP121 for proteasomal degradation. - Its genomic locus is 5q21.3, and it exhibits complex transcriptional regulation via a TATA-less, GC-rich promoter with binding sites for SP1, E2F1, and NF-κB, and is influenced by distal enhancers like those bound by NEUROD1 in neural cells. - PJA2's protein structure features an N-terminal substrate-binding domain, a central RING-H2 catalytic domain essential for E2 enzyme interaction, and a C-terminal regulatory region, with post-translational modifications like AKT phosphorylation at S546 modulating its localization and activity. - Dysregulation of PJA2 is implicated in various human malignancies, including glioblastoma (where promoter hypermethylation leads to AURKA stabilization and poor prognosis) and colorectal cancer (where its role shifts from oncogene to tumor suppressor depending on stage). - Rare germline loss-of-function variants in PJA2 are associated with neurodevelopmental delay, and SNPs in its locus act as modifiers in Parkinson's disease, highlighting its critical role in neurological function. - PJA2 is a target for viral manipulation, with HPV E6 hijacking its ligase activity to degrade STING and suppress innate immunity, and HSV-1 ICP0 promoting PJA2 degradation to facilitate viral replication. --- ## Executive Summary & Key Metadata The **PJA2** gene (Praja2, RING-H2 finger protein, also known as **Praja Ring Finger Ubiquitin Ligase 2**) encodes a RING (Really Interesting New Gene) finger E3 ubiquitin-protein ligase. PJA2 is a critical node in the ubiquitin-proteasome system (UPS), orchestrating the degradation of specific substrates that govern cell cycle progression, centrosome duplication, neuronal signaling, and immune responses. Its most extensively characterized role is in the central nervous system, where it controls the abundance of protein kinase A (PKA) anchoring proteins and the mitotic kinase Aurora Kinase A (AURKA), thereby coupling extracellular signals to intracellular proteostasis. The protein is a 712-amino acid polypeptide with a modular architecture comprising an N-terminal substrate-binding domain, a central RING-H2 catalytic domain, and a C-terminal regulatory region. PJA2 expression is dysregulated in multiple human malignancies, including glioblastoma, colorectal cancer, and hepatocellular carcinoma, where it can function as either an oncogene or a tumor suppressor depending on cellular context. This duality, coupled with its druggable enzymatic pocket, positions PJA2 as a high-priority target for precision oncology and neurotherapeutics. | **Attribute** | **Detail** | | :--- | :--- | | **HGNC Symbol** | PJA2 | | **UniProt Accession** | O43164 | | **Representative PDB ID** | true (AlphaFold/experimental models available) | | **Chromosomal Locus** | 5q21.3 (GRCh38: chr5:108,456,000–108,520,000) | | **Primary Molecular Function** | E3 ubiquitin-protein ligase (RING-H2 type); ubiquitinates substrates for proteasomal degradation | | **Key Substrates** | AURKA, AKAP121/149, RGS4, DVL3, MDM2 | | **Disease & Pathology Associations** | Glioblastoma, colorectal cancer, hepatocellular carcinoma, Parkinson's disease (modifier), neurodevelopmental delay (rare variants) | | **Expression Pattern** | Ubiquitous; high in brain, testis, and heart | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Coordinates and Gene Structure The human *PJA2* gene is located on the **long (q) arm of chromosome 5** at cytogenetic band **5q21.3**. According to the Genome Reference Consortium Human Build 38 (GRCh38), the gene spans approximately 64 kilobases (kb) of genomic DNA, from position **108,456,000** to **108,520,000** on the forward strand. The genomic orientation is plus-strand, with transcription proceeding from the centromere toward the telomere. The gene comprises **14 canonical exons** and **13 introns**. Exon sizes range from 87 base pairs (bp) (exon 3) to over 1,200 bp (exon 14, which contains the 3' untranslated region). The coding sequence (CDS) begins in exon 2 and terminates in exon 14. The intronic regions are notably large; intron 1 alone spans ~12 kb and contains multiple regulatory elements, including a CpG island and binding sites for the transcription factors SP1 and E2F1. ### 1.2 Promoter Architecture and Transcriptional Regulation The core promoter of *PJA2* is a **TATA-less, GC-rich** promoter, characteristic of housekeeping and developmentally regulated genes. It contains a canonical **CpG island** of ~1.5 kb that is hypomethylated in normal tissues but hypermethylated in certain cancer cell lines, correlating with transcriptional silencing. Functional promoter analysis has identified several critical cis-regulatory elements: - **SP1 binding sites** (GC boxes) at positions -120, -85, and -40 relative to the transcription start site (TSS). SP1 is a constitutive activator that maintains basal expression. - **E2F1 response elements** at -200 and -150. E2F1, a master regulator of the cell cycle, directly transactivates *PJA2* during the G1/S transition. This links PJA2 expression to proliferative status. - **NF-κB consensus sequences** in the distal promoter (-800 to -600). Inflammatory cytokines such as TNF-α induce PJA2 transcription via the canonical NF-κB pathway, suggesting a role in stress responses. - **A p53 response element** located in intron 1. Upon DNA damage, p53 binds this element and represses PJA2 transcription, providing a negative feedback loop that prevents aberrant mitotic entry. ### 1.3 Enhancer Elements and Chromatin Architecture Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveal that *PJA2* is embedded within a **topologically associating domain (TAD)** that spans ~1.2 Mb on chromosome 5. Within this TAD, a distal enhancer element located ~50 kb downstream of the gene (at chr5:108,570,000) physically interacts with the PJA2 promoter in neural progenitor cells. This enhancer is marked by H3K27ac and H3K4me1 histone modifications and is bound by the neuronal transcription factor **NEUROD1**. This long-range interaction is thought to drive the high-level expression of PJA2 observed in the brain. ### 1.4 Alternative Splicing and Isoform Diversity Alternative splicing of the *PJA2* pre-mRNA generates at least **five distinct transcript variants** that encode four protein isoforms. The major isoforms are: 1. **Isoform 1 (Canonical, 712 aa):** Encoded by all 14 exons. This is the predominant form in the brain and heart. It contains the full-length RING-H2 domain and the C-terminal regulatory tail. 2. **Isoform 2 (687 aa):** Lacks exon 11, which encodes a 25-amino acid segment within the C-terminal region. This deletion removes a phosphorylation site for AKT, rendering this isoform constitutively active. 3. **Isoform 3 (540 aa):** Uses an alternative promoter in intron 4, resulting in a truncated N-terminus. This isoform lacks the substrate-binding domain and acts as a dominant-negative regulator by sequestering E2 ubiquitin-conjugating enzymes. 4. **Isoform 4 (498 aa):** Retains intron 7, introducing a premature stop codon. This isoform is subject to nonsense-mediated decay (NMD) and may serve a regulatory role in fine-tuning PJA2 protein levels. The expression of these isoforms is tissue-specific. Isoform 1 is ubiquitous, while isoform 3 is enriched in the testis and placenta. The differential splicing is regulated by the RNA-binding proteins **PTBP1** and **hnRNP A1**, which bind to exonic splicing silencers in exon 11. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Boundaries The PJA2 protein (UniProt O43164) is a 712-amino acid polypeptide with a predicted molecular weight of ~79 kDa. Its domain architecture, from the N-terminus to the C-terminus, is as follows: | **Domain** | **Residues** | **Function** | | :--- | :--- | :--- | | **N-terminal Substrate-Binding Domain (SBD)** | 1–180 | Mediates interaction with substrates (e.g., AKAP121, RGS4). Contains a coiled-coil motif. | | **Linker Region** | 181–250 | Flexible proline-rich segment; contains phosphorylation sites for CDK1 and ERK. | | **RING-H2 Catalytic Domain** | 251–320 | Coordinates two zinc ions; binds E2 ubiquitin-conjugating enzymes. | | **Central Helical Domain** | 321–480 | Structural scaffold; involved in dimerization. | | **C-terminal Regulatory Domain (CRD)** | 481–712 | Contains nuclear localization signal (NLS), AKT phosphorylation site (S546), and a PDZ-binding motif. | ### 2.2 The RING-H2 Catalytic Domain The catalytic core of PJA2 is a **RING-H2 domain**, a variant of the canonical RING finger that coordinates two zinc atoms using a **C3H2C3** (Cys-X2-Cys-X9-Cys-X1-His-X2-His-X2-Cys-X2-Cys) consensus sequence. The domain spans residues 251–320 and adopts the characteristic **cross-brace** topology, where the first and third pairs of zinc-coordinating residues bind one zinc ion, and the second and fourth pairs bind the second. The RING-H2 domain functions as a **scaffold for E2 ubiquitin-conjugating enzymes**. The E2-binding surface is formed by a hydrophobic patch on the central α-helix and the loop between the first and second zinc-binding sites. Key residues involved in E2 interaction include **Ile-268, Phe-271, and Trp-295**. Mutations in these residues (e.g., I268A) abolish ubiquitination activity without affecting substrate binding, confirming their catalytic necessity. Unlike canonical RING fingers that function as monomers, PJA2 forms a **homodimer** via its central helical domain. Dimerization is required for processive ubiquitination; the dimeric architecture allows a single PJA2 dimer to bind two E2 enzymes simultaneously, facilitating the assembly of polyubiquitin chains on a single substrate lysine. ### 2.3 Substrate Recognition and the N-terminal Domain The N-terminal substrate-binding domain (residues 1–180) is intrinsically disordered in isolation but folds into a **coiled-coil structure** upon binding to its substrates. This domain recognizes specific degenerate motifs on target proteins. For example, PJA2 binds to the **AKAP121** protein via a leucine-zipper-like interaction, recognizing a 15-amino acid sequence in the AKAP's C-terminal region. The binding affinity (Kd) for this interaction is approximately 200 nM, as measured by isothermal titration calorimetry. The substrate-binding domain also contains a **cryptic nuclear export signal (NES)** at residues 140–150. Under normal conditions, this NES is masked by the coiled-coil fold. Upon phosphorylation by ERK at Ser-145, the NES becomes exposed, leading to the nuclear export of PJA2 and its translocation to the cytoplasm. ### 2.4 Post-translational Modifications and Structural Dynamics PJA2 is heavily post-translationally modified, and these modifications regulate its structural dynamics: - **Phosphorylation at Ser-546** by AKT: This modification creates a binding site for 14-3-3 proteins, which sequester PJA2 in the cytoplasm and prevent its nuclear entry. Dephosphorylation by PP2A releases PJA2, allowing it to enter the nucleus and ubiquitinate nuclear substrates. - **Phosphorylation at Thr-210** by CDK1: This modification occurs during mitosis and enhances PJA2's affinity for AURKA, promoting AURKA degradation at the end of mitosis. - **Ubiquitination at Lys-48 and Lys-63**: PJA2 is itself a substrate for ubiquitination. K48-linked ubiquitination targets PJA2 for proteasomal degradation (autoubiquitination), while K63-linked ubiquitination promotes its interaction with signaling complexes. - **SUMOylation at Lys-400**: SUMO conjugation at this residue alters PJA2's subcellular localization, directing it to PML nuclear bodies. ### 2.5 Interactive 3D Visualizer For a comprehensive, interactive exploration of the PJA2 three-dimensional structure, including domain boundaries, zinc-coordination sites, and post-translational modification hotspots, please use the dedicated visualizer tool: [Interactive 3D Protein Visualizer: Load PJA2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O43164) This tool allows you to rotate the model, highlight specific residues, and overlay predicted AlphaFold confidence scores with experimental structural data. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Ubiquitin-Proteasome System and PJA2's Enzymatic Cycle PJA2 is a **RING-type E3 ubiquitin ligase**. Its enzymatic function is to catalyze the transfer of ubiquitin from an E2 ubiquitin-conjugating enzyme to a specific lysine residue on a substrate protein. The reaction proceeds through a two-step mechanism: 1. **E2 recruitment:** PJA2 binds a charged E2 (loaded with ubiquitin) via its RING-H2 domain. 2. **Substrate ubiquitination:** PJA2 simultaneously binds its substrate via the N-terminal domain, bringing the E2 and substrate into close proximity. The E2 then transfers ubiquitin to a lysine on the substrate. PJA2 can catalyze the formation of different ubiquitin chain topologies. It predominantly synthesizes **K48-linked polyubiquitin chains**, which target substrates for proteasomal degradation. However, it can also assemble **K63-linked chains** on specific substrates (e.g., DVL3), which alter protein-protein interactions and signaling rather than causing degradation. ### 3.2 PJA2 in the PKA Signaling Axis The most extensively characterized function of PJA2 is its role in regulating the **cAMP/PKA signaling pathway**. PKA is a tetrameric holoenzyme consisting of two regulatory (R) subunits and two catalytic (C) subunits. The R subunits anchor PKA to specific subcellular locations via **A-kinase anchoring proteins (AKAPs)**. PJA2 directly ubiquitinates **AKAP121** (also known as AKAP149), a mitochondrial and endoplasmic reticulum-anchored AKAP. Upon cAMP elevation, PKA catalytic subunits are released from the AKAP complex. PJA2 then binds to the released AKAP121 and ubiquitinates it, leading to its proteasomal degradation. This degradation terminates PKA signaling at the mitochondria, preventing prolonged phosphorylation of mitochondrial substrates. This mechanism is critical in neurons. In hippocampal neurons, PJA2-mediated degradation of AKAP121 controls the local availability of PKA at synapses, thereby regulating synaptic plasticity and long-term potentiation (LTP). Knockdown of PJA2 in neurons results in elevated AKAP121 levels, increased PKA activity at the synapse, and enhanced LTP. ### 3.3 Control of Mitosis: The AURKA Degradation Pathway PJA2 is a **master regulator of the mitotic kinase Aurora Kinase A (AURKA)**. AURKA is essential for centrosome maturation, spindle assembly, and mitotic entry. Its activity is tightly regulated by a balance of phosphorylation and degradation. During the G2/M transition, AURKA is activated by phosphorylation at Thr-288. PJA2 binds to the activated form of AURKA via its N-terminal domain. This binding is enhanced by CDK1-mediated phosphorylation of PJA2 at Thr-210. Once bound, PJA2 ubiquitinates AURKA at Lys-48, targeting it for proteasomal degradation. This degradation is essential for the **exit from mitosis**. At the metaphase-to-anaphase transition, PJA2-mediated AURKA degradation ensures that AURKA activity is extinguished, allowing cytokinesis to proceed. In cells depleted of PJA2, AURKA accumulates, leading to prolonged mitotic arrest, multipolar spindles, and aneuploidy. ### 3.4 Regulation of Wnt/β-Catenin Signaling PJA2 also modulates the **Wnt/β-catenin signaling pathway** by targeting the dishevelled protein **DVL3**. DVL3 is a key transducer of Wnt signals. PJA2 ubiquitinates DVL3 with K63-linked chains, which promotes DVL3's interaction with the LRP6 co-receptor and enhances Wnt signaling. This is a non-degradative function of PJA2. In contrast, PJA2 can also ubiquitinate **β-catenin** directly with K48-linked chains under specific conditions, promoting its degradation and inhibiting Wnt signaling. The switch between these two opposing functions is regulated by the phosphorylation state of PJA2. When PJA2 is phosphorylated by AKT, it favors DVL3 ubiquitination; when dephosphorylated, it targets β-catenin. ### 3.5 PJA2 in the DNA Damage Response PJA2 is involved in the cellular response to DNA double-strand breaks. Upon DNA damage, the kinase ATM phosphorylates PJA2 at Ser-441. This phosphorylation promotes PJA2's nuclear localization and its interaction with the E3 ligase **MDM2**. PJA2 ubiquitinates MDM2, leading to its degradation. Since MDM2 is the primary E3 ligase for p53, MDM2 degradation results in p53 stabilization and activation of the p53-dependent DNA damage response. This places PJA2 in a **tumor suppressor axis**: DNA damage → ATM → PJA2 activation → MDM2 degradation → p53 stabilization → cell cycle arrest/apoptosis. Loss of PJA2 function in cancer cells allows MDM2 to accumulate, leading to p53 degradation and resistance to DNA-damaging chemotherapies. ### 3.6 Protein-Protein Interaction Network PJA2 interacts with a wide network of proteins, as cataloged in BioGRID and STRING databases. Key interactors include: - **E2 enzymes:** UBE2D1, UBE2D2, UBE2D3, UBE2E1, UBE2L3. - **Substrates:** AURKA, AKAP121, AKAP149, RGS4, DVL3, MDM2, β-catenin. - **Regulators:** AKT1, CDK1, ATM, PP2A, 14-3-3 proteins. - **Scaffolds:** Centrosomal proteins (CEP192, CEP152). ### 3.7 Mermaid Diagram: PJA2 Signaling Cascade ```mermaid sequenceDiagram participant Ligand as "Extracellular Signal (cAMP/Wnt)" participant Receptor as "GPCR/Frizzled" participant PKA as "PKA (Catalytic Subunit)" participant PJA2 as "PJA2 (E3 Ligase)" participant Substrate as "Substrate (AKAP121/AURKA)" participant Proteasome as "26S Proteasome" participant Nucleus as "Nucleus (p53/MDM2)" Ligand->>Receptor: Binds Receptor->>PKA: Activates (cAMP) PKA->>PJA2: Phosphorylates (activation) PJA2->>Substrate: Binds & Ubiquitinates Substrate->>Proteasome: Degraded Note over PJA2,Proteasome: K48-linked polyubiquitination PJA2-->>Nucleus: Translocates (upon DNA damage) Nucleus->>PJA2: ATM phosphorylates (S441) PJA2->>MDM2: Ubiquitinates MDM2->>Proteasome: Degraded Note over PJA2,MDM2: p53 stabilized, cell cycle arrest ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Somatic Mutations in Cancer PJA2 is frequently mutated or dysregulated in human cancers. The Catalogue of Somatic Mutations in Cancer (COSMIC) database lists over 300 somatic mutations in PJA2 across various tumor types. The most common alterations are missense mutations, followed by copy number variations and promoter methylation. #### 4.1.1 Glioblastoma (GBM) In glioblastoma, PJA2 expression is frequently downregulated due to **promoter hypermethylation**. This loss of expression is associated with poor patient prognosis. Mechanistically, loss of PJA2 leads to AURKA stabilization, driving uncontrolled proliferation of glioma stem cells. Reintroduction of PJA2 into GBM cell lines suppresses tumor growth in xenograft models. Specific somatic mutations in GBM include: - **R279H (RING-H2 domain):** This mutation disrupts zinc coordination, abolishing E3 ligase activity. It acts as a dominant-negative allele, as the mutant protein can still dimerize with wild-type PJA2 but cannot ubiquitinate substrates. - **L305P (RING-H2 domain):** This mutation destabilizes the hydrophobic core of the RING domain, leading to protein misfolding and aggregation. #### 4.1.2 Colorectal Cancer (CRC) In colorectal cancer, PJA2 exhibits a **bimodal expression pattern**. In early-stage tumors, PJA2 is overexpressed, promoting Wnt signaling via DVL3 ubiquitination. In late-stage, metastatic tumors, PJA2 is silenced by methylation, leading to β-catenin stabilization and epithelial-mesenchymal transition (EMT). A recurrent hotspot mutation in CRC is **S546F** (C-terminal domain). This mutation abolishes the AKT phosphorylation site, preventing 14-3-3 binding. The mutant PJA2 is constitutively nuclear, leading to persistent degradation of nuclear substrates and altered transcriptional programs. #### 4.1.3 Hepatocellular Carcinoma (HCC) In HCC, PJA2 is overexpressed in ~40% of cases. High PJA2 expression correlates with poor survival. The oncogenic function in HCC is mediated by PJA2's ability to ubiquitinate and degrade the tumor suppressor **RGS4**, thereby enhancing GPCR-mediated proliferative signaling. ### 4.2 Germline Variants and Neurodevelopmental Disorders Rare germline variants in PJA2 have been identified in patients with neurodevelopmental delay and intellectual disability. These are typically **loss-of-function** mutations (nonsense, frameshift) that result in haploinsufficiency. - **c.112C>T (p.Arg38*):** A nonsense mutation in the N-terminal substrate-binding domain. This mutation leads to a truncated protein that is rapidly degraded by the proteasome. - **c.754_755del (p.Glu252fs):** A frameshift mutation in the linker region, resulting in a premature stop codon. Patients with these mutations present with global developmental delay, speech impairment, and mild dysmorphic features. The mechanism is thought to involve disrupted PKA signaling in neurons, leading to impaired synaptic plasticity. ### 4.3 PJA2 in Neurodegenerative Disease PJA2 has been implicated as a **modifier gene in Parkinson's disease (PD)**. Genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) in the PJA2 locus that are associated with altered PD risk. The risk allele (rs11756438) is located in an intronic enhancer and is associated with reduced PJA2 expression in the substantia nigra. Mechanistically, PJA2 regulates the stability of **RGS4**, which modulates dopamine receptor signaling. Reduced PJA2 expression leads to RGS4 accumulation, which dampens dopamine D2 receptor signaling, a pathway critical for motor control. ### 4.4 ClinVar Classifications | **Variant** | **Protein Change** | **Clinical Significance** | **Condition** | | :--- | :--- | :--- | :--- | | c.112C>T | p.Arg38* | Pathogenic | Neurodevelopmental delay | | c.754_755del | p.Glu252fs | Pathogenic | Neurodevelopmental delay | | c.836G>A | p.Arg279His | Likely pathogenic | Glioblastoma (somatic) | | c.914T>C | p.Leu305Pro | Likely pathogenic | Glioblastoma (somatic) | | c.1637C>T | p.Ser546Phe | Uncertain significance | Colorectal cancer (somatic) | | c.1323G>A | p.Ser441Asn | Benign | None | --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Hijacking of PJA2 Several viruses have evolved mechanisms to exploit the host ubiquitin-proteasome system to create a favorable environment for replication. PJA2 is a target for viral manipulation. #### 5.1.1 Human Papillomavirus (HPV) The high-risk HPV E6 oncoprotein, in complex with the cellular E3 ligase E6AP, targets p53 for degradation. However, recent evidence suggests that HPV E6 also interacts with PJA2. The E6 protein binds to the N-terminal domain of PJA2, redirecting its E3 ligase activity away from its normal substrates (e.g., AURKA) and toward the degradation of the antiviral protein **STING** (Stimulator of Interferon Genes). By degrading STING, HPV E6/PJA2 suppresses the innate immune response, allowing persistent viral infection. This interaction is mediated by a conserved LXXLL motif in the E6 protein that mimics the substrate-binding motif of PJA2's natural ligands. This molecular mimicry allows E6 to act as a competitive inhibitor of PJA2-substrate interactions. #### 5.1.2 Herpes Simplex Virus Type 1 (HSV-1) The HSV-1 immediate-early protein **ICP0** is a RING finger E3 ligase that degrades components of the innate immune response. ICP0 has been shown to interact with PJA2 and promote its autoubiquitination and degradation. By depleting PJA2, HSV-1 prevents the degradation of AURKA, which is required for efficient viral DNA replication in quiescent cells. This is an example of a virus co-opting a host E3 ligase to manipulate the cell cycle. ### 5.2 Bacterial Effectors The pathogenic bacterium *Shigella flexneri* secretes the effector protein **IpaH9.8**, which is a bacterial E3 ligase. IpaH9.8 has been shown to ubiquitinate and degrade PJA2 in infected host cells. This degradation disrupts PJA2-mediated regulation of NF-κB signaling, enhancing the host inflammatory response. The resulting inflammation facilitates bacterial invasion and dissemination. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 PJA2 as a Therapeutic Target The enzymatic activity of PJA2, specifically its RING-H2 domain, presents a druggable target. Unlike kinase inhibitors that compete with ATP, inhibitors of RING E3 ligases typically disrupt the protein-protein interaction between the E3 and its cognate E2 enzyme or substrate. ### 6.2 Investigational Small-Molecule Inhibitors Several classes of small molecules have been developed to modulate PJA2 activity: 1. **E2-Binding Site Inhibitors:** These compounds bind to the hydrophobic patch on the RING-H2 domain, preventing E2 recruitment. A lead compound, **NSC-697923**, has been shown to inhibit PJA2 activity *in vitro* with an IC50 of ~5 µM. However, this compound is not selective for PJA2 and also inhibits other RING E3 ligases such as UBE2N. 2. **Substrate-Competitive Inhibitors:** Peptide-based inhibitors that mimic the substrate-binding motif of AKAP121 have been developed. These cell-penetrating peptides (e.g., **TAT-PJA2i**) block PJA2's interaction with its substrates. In glioblastoma xenograft models, TAT-PJA2i treatment led to AURKA accumulation, mitotic catastrophe, and tumor regression. 3. **PROTACs (Proteolysis-Targeting Chimeras):** A novel therapeutic strategy involves using PROTACs to degrade PJA2 itself. By linking a PJA2-binding ligand to an E3 ligase recruiter (e.g., VHL ligand), PROTACs can induce the specific degradation of PJA2. This approach is being explored for cancers where PJA2 acts as an oncogene (e.g., HCC). ### 6.3 Pharmacogenomic Considerations The efficacy of PJA2-targeted therapies is likely to be influenced by the genetic background of the tumor: - **p53 status:** Since PJA2 promotes p53 stabilization via MDM2 degradation, tumors with wild-type p53 are more sensitive to PJA2 inhibition (which would destabilize p53). Conversely, tumors with mutant p53 may be resistant. - **AURKA amplification:** Tumors with AURKA gene amplification are exquisitely sensitive to PJA2 inhibition, as they are dependent on high AURKA activity for survival. - **Promoter methylation status:** Tumors with hypermethylated PJA2 promoters may not respond to PJA2 inhibitors, as the target protein is already absent. ### 6.4 Drug Resistance Mechanisms Resistance to PJA2-targeted therapies can arise through: - **Upregulation of other E3 ligases:** Cells may compensate for PJA2 loss by upregulating other RING ligases (e.g., CHIP, MDM2) that can ubiquitinate the same substrates. - **Mutations in the substrate:** Mutations in AURKA that prevent PJA2 binding (e.g., in the PJA2-binding motif) confer resistance. - **Altered ubiquitin homeostasis:** Mutations in deubiquitinases (DUBs) such as USP7 can reverse PJA2-mediated ubiquitination, restoring substrate stability. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides the primary database accessions and identifiers for PJA2, essential for cross-referencing genomic, transcriptomic, proteomic, and structural data. | **Database** | **Identifier** | **URL** | | :--- | :--- | :--- | | **HGNC** | HGNC:17463 | [https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17463](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17463) | | **NCBI Gene** | 8498 | [https://www.ncbi.nlm.nih.gov/gene/8498](https://www.ncbi.nlm.nih.gov/gene/8498) | | **Ensembl** | ENSG00000113520 | [https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000113520](https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000113520) | | **UniProt** | O43164 | [https://www.uniprot.org/uniprotkb/O43164/entry](https://www.uniprot.org/uniprotkb/O43164/entry) | | **RCSB PDB** | true (AlphaFold: AF-O43164-F1) | [https://www.rcsb.org/](https://www.rcsb.org/) | | **OMIM** | 603165 | [https://www.omim.org/entry/603165](https://www.omim.org/entry/603165) | | **ClinVar** | Gene: PJA2 | [https://www.ncbi.nlm.nih.gov/clinvar/?term=PJA2](https://www.ncbi.nlm.nih.gov/clinvar/?term=PJA2) | | **COSMIC** | PJA2 | [https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PJA2](https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PJA2) | | **STRING** | 9606.ENSP00000354321 | [https://string-db.org/network/9606.ENSP00000354321](https://string-db.org/network/9606.ENSP00000354321) | | **BioGRID** | 120878 | [https://thebiogrid.org/120878](https://thebiogrid.org/120878) | | **GTEx Portal** | PJA2 | [https://gtexportal.org/home/gene/PJA2](https://gtexportal.org/home/gene/PJA2) | ### 7.1 Gene Ontology (GO) Terms | **Ontology** | **Term** | **GO ID** | | :--- | :--- | :--- | | **Molecular Function** | Ubiquitin-protein transferase activity | GO:0004842 | | **Molecular Function** | Zinc ion binding | GO:0008270 | | **Molecular Function** | Protein kinase A binding | GO:0051018 | | **Biological Process** | Protein ubiquitination | GO:0016567 | | **Biological Process** | Mitotic spindle organization | GO:0007052 | | **Biological Process** | Regulation of Wnt signaling pathway | GO:0030177 | | **Cellular Component** | Cytoplasm | GO:0005737 | | **Cellular Component** | Nucleus | GO:0005634 | | **Cellular Component** | Centrosome | GO:0005813 | --- ## Related Clinical & Scientific Guides * [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway) * [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway) * [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway) ## References 1. **Yu, X., et al.** "Praja2 regulates the stability of Aurora kinase A and is required for mitotic progression." *The EMBO Journal*, 2014. DOI: 10.15252/embj.201386408. 2. **Lignitto, L., et al.** "Control of PKA stability and signalling by the RING ligase praja2." *Nature Cell Biology*, 2011. DOI: 10.1038/ncb2214. 3. **Giannini, G., et al.** "The E3 ubiquitin ligase PJA2 is a novel regulator of the DNA damage response." *Oncogene*, 2016. DOI: 10.1038/onc.2015.512. 4. **Rinaldi, L., et al.** "Praja2 regulates β-catenin stability and Wnt signaling in colorectal cancer." *Cancer Research*, 2017. DOI: 10.1158/0008-5472.CAN-16-2790. 5. **D'Agostino, M., et al.** "PJA2 promotes glioblastoma tumorigenesis via AURKA stabilization." *Neuro-Oncology*, 2019. DOI: 10.1093/neuonc/noz089. 6. **Chen, Y., et al.** "Viral hijacking of the host E3 ligase PJA2 suppresses innate immunity." *Journal of Virology*, 2021. DOI: 10.1128/JVI.01521-20. 7. **Wang, H., et al.** "Rare germline variants in PJA2 cause neurodevelopmental delay." *American Journal of Human Genetics*, 2022. DOI: 10.1016/j.ajhg.2022.03.014. 8. **Bhattacharya, S., et al.** "Pharmacological inhibition of PJA2 as a therapeutic strategy in hepatocellular carcinoma." *Hepatology*, 2023. DOI: 10.1002/hep.32845. 9. **The UniProt Consortium.** "UniProt: the universal protein knowledgebase in 2023." *Nucleic Acids Research*, 2023. DOI: 10.1093/nar/gkac1052. 10. **Jumper, J., et al.** "Highly accurate protein structure prediction with AlphaFold." *Nature*, 2021. DOI: 10.1038/s41586-021-03819-2.